Ray Dalio’s Novo Nordisk NVO Stock Holding History

Ray Dalio’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-138,947	Closed	-$7.71M	–	1141
2025 Q3	$7.71M	Buy	+138,947	New	+$8.13M	0.03%	385

Other funds holding NVO

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Ray Dalio's NVO Position: Q4 2025 in Review

Ray Dalio sold out of Novo Nordisk (NVO) in Q4 2025, closing a stake of 138,947 shares — an estimated $7.71M sold.

Ray Dalio first reported a position in NVO in Q3 2025 and held it in 1 quarter. The position peaked at $7.71M in Q3 2025. 1,416 funds tracked by Wall St. Rank hold NVO as of Q4 2025.

Ray Dalio reported no remaining Novo Nordisk position as of Q4 2025 after selling out during the quarter.
Ray Dalio sold 138,947 Novo Nordisk shares in Q4 2025, an estimated $7.71M.
Ray Dalio first reported a position in Novo Nordisk in Q3 2025 and held it in 1 quarter.
Ray Dalio's Novo Nordisk position peaked at $7.71M in Q3 2025.
1,416 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2025.

Based on Bridgewater Associates's 13F filing for Q4 2025, filed 13 Feb 2026.